Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8214792 | 0.83 | ALDH1A1 (0.36) | SMN1; SMN2USP2ALDH1A1GAAMEN1 | |
| SCHEMBL18775073 | 0.81 | ALDH1A1 (0.36) | SMN1; SMN2USP2ALDH1A1GAAMEN1 | |
| SCHEMBL1709046 | 0.80 | — | — | |
| SCHEMBL24182620 | 0.80 | ALDH1A1 (0.35) | SMN1; SMN2USP2ALDH1A1GAAMEN1 | |
| SCHEMBL18859426 | 0.78 | CYP2B6 (0.32) | — | |
| SCHEMBL16975531 | 0.73 | MEN1 (0.42) | ALDH1A1GAAMEN1KMT2AL3MBTL1 | |
| SCHEMBL16075552 | 0.73 | MAPT (0.41) | SMN1; SMN2USP2ALDH1A1KMT2AL3MBTL1 | |
| SCHEMBL9921756 | 0.73 | ALDH1A1 (0.38) | SMN1; SMN2ALDH1A1GAAMEN1KMT2A | |
| SCHEMBL17393082 | 0.73 | ALDH1A1 (0.38) | SMN1; SMN2ALDH1A1GAAMEN1KMT2A | |
| SCHEMBL23919087 | 0.72 | USP2 (0.34) | SMN1; SMN2USP2ALDH1A1GAAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170137420-A1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS P13K INHIBITOR | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2017-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137420-A1 | PYRIDINO[1,2-A]PYRIMIDONE ANALOGUE USED AS P13K INHIBITOR | PIK3CA, PIK3CD, PIP5K1B | SMN1; SMN2 2730/4885USP2 3459/4885ALDH1A1 1052/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.